Physician profile
Farhan Katchi
NPI 1396031225
$30,713.67
in general payments reported to CMS, 2019-2025
19 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $201 · 2021: $130 · 2022: $150 · 2023: $381 · 2024: $522 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,750 · Travel and Lodging: $4,285 · Food and Beverage: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,975.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,750.00 |
| Travel and Lodging | $4,284.70 |
| Food and Beverage | $2,147.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $15,028.80 | 2022-2025 | Ffrct |
| United Imaging Healthcare North America, INC. | $10,725.00 | 2025 | Ultrasound |
| Agepha Pharma Fz LLC | $2,331.69 | 2025 | Lodoco |
| Amgen INC. | $821.44 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $495.20 | 2019 | |
| Pfizer INC. | $257.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $189.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $158.60 | 2019-2025 | Camzyos |
| Abiomed | $118.32 | 2023 | Impella |
| Cleerly, INC. | $113.42 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Astrazeneca Pharmaceuticals LP | $99.99 | 2020 | |
| Novo Nordisk INC | $96.27 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $63.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.32 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.53 | 2019-2020 | |
| Cvrx, INC. | $24.86 | 2021 | |
| Edwards Lifesciences Corporation | $21.15 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Katchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.